Related Experiment Video

Updated: Jun 25, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Retinoids differentially regulate the progression of autoimmune diabetes in three preclinical models in mice

Stanislava Stosić-Grujicić1, Tamara Cvjetićanin, Ivana Stojanović

  • 1Department of Immunology, Institute for Biological Research Sinisa Stanković, Belgrade University, Bulevar Despota Stefana 142, 11060 Belgrade, Serbia. duta@eunet.rs

Molecular Immunology
|February 13, 2009
PubMed

Insights

Retinoids like etretinate and all-trans-retinoic acid (ATRA) show promise in preventing type 1 diabetes (T1D) by modulating immune responses. Their effectiveness in preclinical models depends on the presence of regulatory T cells (Tregs).

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Retinoids possess immunomodulatory properties relevant to inflammatory and autoimmune diseases.
  • Type 1 diabetes (T1D) involves complex autoimmune pathogenesis.
  • Understanding T1D's immune triggers is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the potential of retinoids, specifically etretinate and all-trans-retinoic acid (ATRA), in preclinical models of T1D.
  • To elucidate the mechanisms underlying retinoid-mediated prevention of T1D.
  • To determine the role of regulatory T cells (Tregs) in retinoid efficacy for T1D.

Main Methods:

  • Prophylactic administration of etretinate and ATRA to streptozotocin-induced diabetic CBA/H mice.
  • Assessment of clinical diabetes signs, immune cell populations (CD4+CD25+ T cells, Foxp3+ Tregs), and cytokine profiles (Th1/Th17, NO).
  • Treatment of non-obese diabetic (NOD) mice with ATRA before T1D onset, including experiments with cyclophosphamide (CY)-induced Treg abrogation.

Main Results:

  • Both etretinate and ATRA prevented clinical T1D in MLD-STZ treated mice.
  • T1D prevention was linked to reduced autoreactive T cells but not increased Tregs.
  • ATRA treatment decreased Th1/Th17 responses and nitric oxide (NO) production.
  • ATRA prophylaxis reduced hyperglycemia and T1D incidence in spontaneous NOD mouse models.
  • ATRA's protective effect was lost when Tregs were abrogated by CY.

Conclusions:

  • Retinoids, including ATRA, can effectively prevent T1D in preclinical models.
  • The immunomodulatory effects of retinoids involve suppressing inflammatory responses and shifting cytokine balance.
  • The therapeutic efficacy of retinoids in T1D is dependent on the presence and function of regulatory T cells (Tregs).

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...